newsletter

SATB2 plays an important role in bone formation by influencing bone cells - specifically the multiplication and differentiation of osteoblasts. Low bone density can occur in children in SAS and likely also in adults, though research data for ages 18+ are still missing. When low bone density is present, the bone tissue has less minerals (f.i. calcium) built-in and as a result can fracture more easily. 

Diagnostics and terminology

To say something about prevalence, it’s necessary to explain about diagnostics and terminology.
Bone density can be measured by a DEXA scan of the hip and lumbar spine. In adults, scores are compared to bone mass in healthy young adults, which is called a T-score. This score is expressed as the difference to the mean score, in standard deviations (SD).
A T-score of 0 is average, a positive score is above average, between -1 and -2 SD is called osteopenia, and a T-score < -2 SD is called osteoporosis.
In children, scores are compared to other children matched for age, sex and size, which is called a Z-score. A Z-score above -2 SD is considered within the expected range for age. A Z-score < -2 SD is called low bone mineral density (BMD) for age, but this alone does not establish a diagnosis of osteoporosis. Only in the presence of clinically significant fractures (e.g. ≥2 long-bone fractures before age 10, or ≥3 before age 19), is a diagnosis of pediatric osteoporosis made.

Prevalence

The largest study done so far, showed that 5 out of 32 children with SAS (16%) had low BMD for age. Two of these had nontraumatic fractures and two had a fracture due to adequate trauma. In another study, 6 of 17 children (35%) had a history of fractures. It is important to note that these children were recruited through a centre for bone diseases, and that the ‘life time risk’ of a bone fracture in children aged 16 years is 27 - 64%. In several studies, high levels of markers for bone turnover (f.i. alkaline phosphatase) have been measured, but so far these do not seem to predict the presence of low BMD or osteoporosis.

Management:
When people with SAS have a bone fracture, it is recommendable to do a DEXA scan to assess bone density. In the absence of fractures, it can also be considered to do a DEXA scan at least once, even at ages as young as 3 to 5 years.
In the case of low bone density (for age) or osteoporosis:

  • assess for modifiable risk factors (vitamin D deficiency, limited mobility, low calcium intake)
  • encourage weight-bearing activity as tolerated
  • have a specialist (paediatrician or paediatric endocrinologist) perform standard follow-up and/or treatment

 

The content provided by this website is for educational, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Always consult with your licensed healthcare provider.

Frequently asked questions

Simple answers for families, supporters, and professionals who want to learn more about SAS and SATB2 Europe.

What is SATB2-associated syndrome?

SATB2-associated syndrome, or SAS, is a rare genetic neurodevelopmental condition caused by changes in the SATB2 gene. It can affect development, speech, learning, behavior, dental health, sleep, seizures, feeding, and bone health.

What are common signs of SAS?

Common features can include developmental delay, limited or absent speech, dental differences, feeding difficulties, sleep challenges, behavioral differences, seizures, and bone health concerns. Not every person has the same symptoms, and the severity can vary widely.

How is SAS diagnosed?

SAS is usually diagnosed through genetic testing. A diagnosis is made when a disease-causing change, deletion, duplication, or disruption involving the SATB2 gene is found. Families should discuss testing and results with a qualified medical professional or genetic counselor.

Is there a cure for SAS?

There is currently no simple cure for SAS. Care usually focuses on supporting development, communication, feeding, sleep, seizures, dental health, bone health, and other individual needs. Research and clinical guidance are important parts of improving future care.